
Because zzso zzso and zzso zzso act zzso in zzso in the generation of zzso killer zzso zzso we initiated a clinical trial of these zzso in zzso Twenty patients with advanced zzso were treated at fixed dose levels of zzso zzso given by intramuscular zzso injections once a day and zzso zzso given by an intravenous zzso zzso injection 3 times a day for 7 days after a zzso treatment with fixed doses zzso zzso of zzso zzso A minimum of four patients were treated at each of the four dose levels zzso The side effects of the combination therapy were similar to those seen with individual zzso and included fever and zzso zzso headache, fatigue, zzso zzso peripheral zzso skin zzso and zzso The maximum tolerated dose for the combination after a fixed dose of zzso was 2 zzso zzso zzso (10 zzso of zzso and 3 zzso zzso zzso of zzso with fluid retention as the zzso zzso Whereas natural killer zzso or zzso activity or both were significantly increased in four of eight patients zzso only one patient with zzso cell cancer had a minor response for four treatment zzso We conclude that combination therapy with zzso zzso and zzso given in this schedule had manageable toxicity and exhibited zzso effects in some patients but had no significant zzso activity in this patient zzso 

